Real World Clinical Outcomes for Metastatic Non-Small Cell Lung Cancer (mNSCLC) at IRST Italy

被引：0
|
作者：
Altini, M. [1 ]
Massa, I. [1 ]
Balzi, W. [1 ]
Gentili, N. [1 ]
Foca, F. [1 ]
Danesi, V. [1 ]
Manunta, S. [1 ]
Ejzykowicz, F. [2 ]
Chandwani, S. [3 ]
Burgio, M. [1 ]
Cravero, P. [1 ]
Verlicchi, A. [1 ]
Bronte, G. [1 ]
Crino, L. [1 ]
Delmonte, A. [1 ]
机构：
[1] IRCCS, Ist Sci Romagnolo Studio & Cura Tumor Irst, Meldola, Italy
[2] Merck & Co Inc, Oncol Prod Line, Core, Kenilworth, NJ USA
[3] Merck & Co Inc, Ctr Observat & Real World Evidence, Kenilworth, NJ USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
treatment pattern; real-world study; Outcomes;
D O I：
10.1016/j.jtho.2019.08.2369
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP1.16-04
引用
收藏
页码：S1065 / S1066
页数：2
相关论文
共 50 条
  • [31] Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer
    Wang, Zhongtai
    Zhang, Hui
    Zhou, Chunhua
    Long, Xiaoyan
    Guan, Rui
    Yang, Nong
    Zhang, Yongchang
    CANCER MEDICINE, 2019, 8 (04): : 1434 - 1441
  • [32] Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004)
    Liu, Si-Yang
    Chen, Qixun
    Zhou, Chengzhi
    Zhang, Huizhong
    Li, Wen
    Chen, Jianhua
    Hu, Jian
    Wu, Lin
    Chen, Qunqing
    Dai, Qiangsheng
    Shan, Jian-Zhen
    Xu, Fei
    Liu, Si-Yang Maggie
    Wu, Yi-Long
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (07) : 2257 - 2265
  • [33] Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis
    Hardtstock, Fraence
    Myers, David
    Li, Tracy
    Cizova, Diana
    Maywald, Ulf
    Wilke, Thomas
    Griesinger, Frank
    BMC CANCER, 2020, 20 (01)
  • [34] Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004)
    Si-Yang Liu
    Qixun Chen
    Chengzhi Zhou
    Huizhong Zhang
    Wen Li
    Jianhua Chen
    Jian Hu
    Lin Wu
    Qunqing Chen
    Qiangsheng Dai
    Jian-Zhen Shan
    Fei Xu
    Si-Yang Maggie Liu
    Yi-Long Wu
    Cancer Immunology, Immunotherapy, 2023, 72 : 2257 - 2265
  • [35] Uniportal VATS for non-small cell lung cancer
    Bulgarelli Maqueda, Luciano
    Garcia-Perez, Alejandro
    Minasyan, Anna
    Gonzalez-Rivas, Diego
    GENERAL THORACIC AND CARDIOVASCULAR SURGERY, 2020, 68 (07) : 707 - 715
  • [36] Impact of Comorbidity Scores on the Overall Survival of Patients With Advanced Non-small Cell Lung Cancer: A Real-World Experience From Eastern India
    Goud, M. Srikanth
    Mohapatra, Prasanta R.
    Bhuniya, Sourin
    Majumdar, Saroj Kumar Das
    Mishra, Pritinanda
    Panigrahi, Manoj K.
    Bal, Shakti K.
    Datta, Ananda
    Venkatachalam, Palanisamy
    Chatterjee, Debopam
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (10)
  • [37] A systematic literature review of real-world treatment outcomes of small cell lung cancer
    Stokes, Michael
    Berfeld, Noami
    Gayle, Alicia
    Descoteaux, Andrew
    Rohrmoser, Oscar
    Franks, April
    MEDICINE, 2022, 101 (26) : E29783
  • [38] Study of patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm+ non-small cell lung cancer
    Winfree, Katherine B.
    Sheffield, Kristin M.
    Cui, Zhanglin Lin
    Sugihara, Tomoko
    Feliciano, Josephine
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (01) : 91 - 99
  • [39] Efficacy and safety of pralsetinib in patients with RET fusion positive non-small cell lung cancer: An observational real world study
    Liao, Dehua
    Long, Minghui
    Zhang, Jiwen
    Wei, Xingyu
    Li, Fei
    Yan, Ting
    Yang, Desong
    LUNG CANCER, 2024, 196
  • [40] Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: a systematic review of real-world data
    Macioch, Tomasz
    Krzakowski, Maciej
    Golebiewska, Klaudia
    Dobek, Malgorzata
    Warchalowska, Natalia
    Niewada, Maciej
    DISCOVER ONCOLOGY, 2024, 15 (01)
12345